Heath Jacqueline, Lehman Erik, Saunders Erika F H, Craig Timothy
Penn State University College of Medicine, Hershey, Pennsylvania, USA.
Allergy Asthma Proc. 2016 Sep;37(5):409-15. doi: 10.2500/aap.2016.37.3977.
Primary immunodeficiency (PID) is a rare group of disorders that manifest similarly with infection, neoplasms, allergic, and autoimmune diseases, and are treated with injectable medications. Often the burden of disease and cost of management is excessive, and premature death is not uncommon. In light of these features of PID, it was our objective to survey our cohort to assess for factors that can influence depression and anxiety.
We used an investigator-developed survey, in addition to the Hamilton Depression Rating Scale (HAM-D) and the Hamilton Anxiety Rating Scale, after institutional review board approval of our pilot study, to determine the extent of anxiety and depression that our patients with PID experienced and variables that may have affected the difference of expression. The differences among groups were tested by using Wilcoxon rank sum tests, Kruskal-Wallis tests, and chi-square tests.
The patients with PID had similar depression compared with the U.S. population, as assessed by the HAM-D scale. Risk factors associated with elevated HAM-D scores included the following: not driving, intravenous immunoglobulin therapy (versus subcutaneous), nurse-administered therapy (versus self-administered), having unpleasant adverse effects from therapy, previously attempted suicide, and family members with reported anxiety and/or depression. Anxiety was not significantly increased in our cohort. Risk factors for significantly elevated Hamilton Anxiety Rating Scale scores included the following: having poor health, an unhealthy diet, lack of refreshing sleep, and family members with reported anxiety and/or depression.
Many factors influence depression and anxiety, and may add to the morbidity of PID. Patients should be assessed for our identified factors for depression and anxiety. Treatment or referrals should be initiated as it is hoped to improve our patients' quality of life and outcomes.
原发性免疫缺陷病(PID)是一组罕见的疾病,其表现与感染、肿瘤、过敏和自身免疫性疾病相似,需用注射药物治疗。通常,疾病负担和管理成本过高,过早死亡并不罕见。鉴于PID的这些特征,我们的目标是对我们的队列进行调查,以评估可能影响抑郁和焦虑的因素。
在我们的初步研究获得机构审查委员会批准后,除了汉密尔顿抑郁量表(HAM-D)和汉密尔顿焦虑量表外,我们还使用了研究者自行编制的调查问卷,以确定PID患者所经历的焦虑和抑郁程度以及可能影响表达差异的变量。组间差异采用Wilcoxon秩和检验、Kruskal-Wallis检验和卡方检验。
根据HAM-D量表评估,PID患者的抑郁程度与美国人群相似。与HAM-D评分升高相关的危险因素包括:不会开车、静脉注射免疫球蛋白治疗(与皮下注射相比)、护士给药治疗(与自我给药相比)、治疗有不愉快的不良反应、曾有自杀未遂、家庭成员有焦虑和/或抑郁报告。我们队列中的焦虑没有显著增加。汉密尔顿焦虑量表评分显著升高的危险因素包括:健康状况差、饮食不健康、睡眠不佳、家庭成员有焦虑和/或抑郁报告。
许多因素影响抑郁和焦虑,可能会增加PID的发病率。应对患者进行我们所确定的抑郁和焦虑因素评估。应启动治疗或转诊,希望能改善患者的生活质量和预后。